Onercept

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2014
02420012014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
  • Kim Papp
  • Current medical research and opinion
  • 2010
BACKGROUND Tumor necrosis factor (TNF)-α plays a critical role in psoriasis pathogenesis, and several anti-TNF agents have been… (More)
Is this relevant?
2010
2010
BACKGROUND Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour… (More)
  • table 1
  • figure 1
Is this relevant?
2007
2007
OBJECTIVE To conduct a robust, double-blind, placebo-controlled study examining the effects of tumor necrosis factor (TNF… (More)
Is this relevant?
2007
2007
Anti-tumor necrosis factor-alpha (anti-TNF) therapy has become a very important modality in the treatment of patients with… (More)
Is this relevant?
2006
2006
BACKGROUND AND AIMS Onercept is a recombinant, soluble human p55 receptor to tumor necrosis factor-alpha. METHODS A randomized… (More)
Is this relevant?
2005
2005
OBJECTIVE To develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics of… (More)
Is this relevant?
Review
2004
Review
2004
Inflammatory bowel disease (IBD) is a chronic immunoinflammatory response to an stimulus that activates a chain of cellular… (More)
Is this relevant?
2003
2003
BACKGROUND Monoclonal antibodies to the pro-inflammatory cytokine tumour necrosis factor-alpha have shown efficacy in treating… (More)
Is this relevant?
Review
2003
Review
2003
Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential… (More)
Is this relevant?
2001
2001
The safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (r-hTBP-1… (More)
Is this relevant?